Recent News

• 11.04.2025 - Cumberland Pharmaceuticals 2025 Q3 earnings call
• 08.05.2025 - Cumberland Pharmaceuticals 2025 Q2 earnings call
• 08.05.2025 - Cumberland Pharmaceuticals 2025 Q2 earnings call
• 08.05.2025 - Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
• 08.04.2025 - CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
• 07.29.2025 - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
• 06.23.2025 - Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
• 05.27.2025 - NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
• 05.13.2025 - CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

Recent Filings

• 08.05.2025 - EX-99.1 EX-99.1
• 08.05.2025 - 8-K Current report
• 07.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.06.2025 - 4 Statement of changes in beneficial ownership of securities